Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer

Randa El-Zein, Sherif Abdel-Rahman, Nivea Conforti-Froes, Scott K. Alpard, Jospeh B. Zwischenberger

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The ability to identify individuals at greatest risk of developing lung cancer can significantly enhance the efficacy of intervention modalities. One strategy for identifying these individuals is through biomarkers that reflect the severity of their cancer. In the present study, we evaluated 22 lung cancer patients and 35 controls to determine whether the frequency of chromosome aberrations was significantly associated with specific clinical variables such as the histological type, grade and stage of the tumors. Chromosome aberrations (expressed as total breaks) were investigated on chromosome 1 in interphase nuclei obtained from blood lymphocytes of the study participants using the fluorescence in situ hybridization (FISH) chromosome aberration assay. Our results indicate a significant linear increase (P = 0.01) in the level of breaks with respect to the grade of the carcinoma. The poorly differentiated tumors had a significantly higher level of chromosome breaks mean ± SD (1.7 ± 0.46) as compared to the well differentiated tumors (0.98 ± 0.23, P < 0.05). These results indicate that chromosome aberrations, as determined by the FISH assay, can be used as a biomarker for identifying individuals with aggressive types of lung cancer and potentially, as a predictor for prognostic outcome of the disease. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalCancer Letters
Volume158
Issue number1
DOIs
StatePublished - Sep 29 2000

Fingerprint

Chromosome Aberrations
Lung Neoplasms
Smoking
Fluorescence In Situ Hybridization
Neoplasms
Biomarkers
Chromosome Breakage
Aptitude
Chromosomes, Human, Pair 1
Interphase
Lymphocytes
Carcinoma

Keywords

  • Chromosome aberrations
  • Fluorescence in situ hybridization
  • Grades
  • Histoplathology
  • Lung cancer
  • Smoking
  • Stages

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer. / El-Zein, Randa; Abdel-Rahman, Sherif; Conforti-Froes, Nivea; Alpard, Scott K.; Zwischenberger, Jospeh B.

In: Cancer Letters, Vol. 158, No. 1, 29.09.2000, p. 65-71.

Research output: Contribution to journalArticle

El-Zein, Randa ; Abdel-Rahman, Sherif ; Conforti-Froes, Nivea ; Alpard, Scott K. ; Zwischenberger, Jospeh B. / Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer. In: Cancer Letters. 2000 ; Vol. 158, No. 1. pp. 65-71.
@article{0816ec309ffe4bcf9c5df17db4b86223,
title = "Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer",
abstract = "The ability to identify individuals at greatest risk of developing lung cancer can significantly enhance the efficacy of intervention modalities. One strategy for identifying these individuals is through biomarkers that reflect the severity of their cancer. In the present study, we evaluated 22 lung cancer patients and 35 controls to determine whether the frequency of chromosome aberrations was significantly associated with specific clinical variables such as the histological type, grade and stage of the tumors. Chromosome aberrations (expressed as total breaks) were investigated on chromosome 1 in interphase nuclei obtained from blood lymphocytes of the study participants using the fluorescence in situ hybridization (FISH) chromosome aberration assay. Our results indicate a significant linear increase (P = 0.01) in the level of breaks with respect to the grade of the carcinoma. The poorly differentiated tumors had a significantly higher level of chromosome breaks mean ± SD (1.7 ± 0.46) as compared to the well differentiated tumors (0.98 ± 0.23, P < 0.05). These results indicate that chromosome aberrations, as determined by the FISH assay, can be used as a biomarker for identifying individuals with aggressive types of lung cancer and potentially, as a predictor for prognostic outcome of the disease. (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Chromosome aberrations, Fluorescence in situ hybridization, Grades, Histoplathology, Lung cancer, Smoking, Stages",
author = "Randa El-Zein and Sherif Abdel-Rahman and Nivea Conforti-Froes and Alpard, {Scott K.} and Zwischenberger, {Jospeh B.}",
year = "2000",
month = "9",
day = "29",
doi = "10.1016/S0304-3835(00)00503-6",
language = "English (US)",
volume = "158",
pages = "65--71",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Chromosome aberrations as a predictor of clinical outcome for smoking associated lung cancer

AU - El-Zein, Randa

AU - Abdel-Rahman, Sherif

AU - Conforti-Froes, Nivea

AU - Alpard, Scott K.

AU - Zwischenberger, Jospeh B.

PY - 2000/9/29

Y1 - 2000/9/29

N2 - The ability to identify individuals at greatest risk of developing lung cancer can significantly enhance the efficacy of intervention modalities. One strategy for identifying these individuals is through biomarkers that reflect the severity of their cancer. In the present study, we evaluated 22 lung cancer patients and 35 controls to determine whether the frequency of chromosome aberrations was significantly associated with specific clinical variables such as the histological type, grade and stage of the tumors. Chromosome aberrations (expressed as total breaks) were investigated on chromosome 1 in interphase nuclei obtained from blood lymphocytes of the study participants using the fluorescence in situ hybridization (FISH) chromosome aberration assay. Our results indicate a significant linear increase (P = 0.01) in the level of breaks with respect to the grade of the carcinoma. The poorly differentiated tumors had a significantly higher level of chromosome breaks mean ± SD (1.7 ± 0.46) as compared to the well differentiated tumors (0.98 ± 0.23, P < 0.05). These results indicate that chromosome aberrations, as determined by the FISH assay, can be used as a biomarker for identifying individuals with aggressive types of lung cancer and potentially, as a predictor for prognostic outcome of the disease. (C) 2000 Elsevier Science Ireland Ltd.

AB - The ability to identify individuals at greatest risk of developing lung cancer can significantly enhance the efficacy of intervention modalities. One strategy for identifying these individuals is through biomarkers that reflect the severity of their cancer. In the present study, we evaluated 22 lung cancer patients and 35 controls to determine whether the frequency of chromosome aberrations was significantly associated with specific clinical variables such as the histological type, grade and stage of the tumors. Chromosome aberrations (expressed as total breaks) were investigated on chromosome 1 in interphase nuclei obtained from blood lymphocytes of the study participants using the fluorescence in situ hybridization (FISH) chromosome aberration assay. Our results indicate a significant linear increase (P = 0.01) in the level of breaks with respect to the grade of the carcinoma. The poorly differentiated tumors had a significantly higher level of chromosome breaks mean ± SD (1.7 ± 0.46) as compared to the well differentiated tumors (0.98 ± 0.23, P < 0.05). These results indicate that chromosome aberrations, as determined by the FISH assay, can be used as a biomarker for identifying individuals with aggressive types of lung cancer and potentially, as a predictor for prognostic outcome of the disease. (C) 2000 Elsevier Science Ireland Ltd.

KW - Chromosome aberrations

KW - Fluorescence in situ hybridization

KW - Grades

KW - Histoplathology

KW - Lung cancer

KW - Smoking

KW - Stages

UR - http://www.scopus.com/inward/record.url?scp=0034730946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034730946&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(00)00503-6

DO - 10.1016/S0304-3835(00)00503-6

M3 - Article

C2 - 10940511

AN - SCOPUS:0034730946

VL - 158

SP - 65

EP - 71

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -